Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 725,000 ordinary shares of 25 pence each.
- Purchase Price: 1,382.85 pence per share.
- Treasury Shares Held: 115,028,000 shares following the transaction.
- Shares in Issue: 5,830,962,735 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed this purchase on September 20, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (725,000 shares at 1,382.85 pence) against the company's cash position in broader financial reports.
- Confirm the updated total share count and Treasury holdings for accurate earnings per share (EPS) calculations.
- Review the authorization limits from the May 25, 2005 Annual General Meeting to determine remaining capacity for future buybacks.